KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 4605 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Posterior cervical foraminotomy versus anterior cervical discectomy for Cervical Brachialgia: the FORVAD RCT. PMID 37929307 · Health Technol Assess · 2023-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial. PMID 37814062 · Nat Med · 2023-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies. PMID 37794745 · Autism Res · 2023-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial. PMID 37783969 · Nat Med · 2023-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Internet-delivered cognitive behavioural therapy programme to reduce depressive symptoms in patients with multiple sclerosis: a multicentre, randomised, controlled, phase 3 trial. PMID 37775187 · Lancet Digit Health · 2023-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. PMID 37739572 · Lancet Neurol · 2023-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. PMID 37709999 · Nat Med · 2023-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Psychometric evaluation of the Worst Pruritus Numerical Rating Scale (NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS). PMID 37691437 · Curr Med Res Opin · 2023-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: Data at 52 weeks post-maribavir treatment initiation. PMID 37657421 · Antivir Ther · 2023-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Phase 3 Clinical Trial Comparing the Safety and Efficacy of Netarsudil to Ripasudil in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Japan Rho Kinase Elevated Intraocular Pressure Treatment Trial (J-ROCKET). PMID 37603205 · Adv Ther · 2023-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Randomized controlled trial of the behavioral intervention for physical activity in multiple sclerosis project: Social cognitive theory variables as mediators. PMID 37586313 · Mult Scler Relat Disord · 2023-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of lemborexant in subjects previously treated with placebo for 6 months in a randomized phase 3 study. PMID 37574610 · Sleep Med · 2023-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial. PMID 37543865 · Epilepsia · 2023-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis. PMID 37525592 · Muscle Nerve · 2023-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial. PMID 37494942 · Lancet HIV · 2023-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Application of an artificial intelligence-based tool in [18F]FDG PET/CT for the assessment of bone marrow involvement in multiple myeloma. PMID 37493665 · Eur J Nucl Med Mol Imaging · 2023-Oct The record describes a primary analysis from a Phase III randomized trial in oncology, but the endpoint is diagnostic validation and correlation, not a time-to-event efficacy outcome for a drug intervention. The abstract does not report OS, PFS, DFS, or other survival metrics, nor Kaplan-Meier curves or hazard ratios. The intervention described is an AI tool for imaging analysis, not a drug therapy. Therefore, it does not meet the inclusion criteria for time-to-event efficacy endpoint and drug intervention.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study. PMID 37402696 · Diabetes Obes Metab · 2023-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy of mometasone/indacaterol/glycopyrronium in patients with inadequately controlled asthma with respect to baseline eosinophil count: Post hoc analysis of IRIDIUM study. PMID 37392789 · Respir Med · 2023-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy. PMID 37366581 · Allergy · 2023-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Predicting Treatment Effects of a New-to-Market Drug in Clinical Practice Based on Phase III Randomized Trial Results. PMID 37365904 · Clin Pharmacol Ther · 2023-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of microencapsulated benzoyl peroxide and microencapsulated tretinoin for the treatment of acne vulgaris: Results from two phase 3 double-blind, randomized, vehicle-controlled studies. PMID 37356627 · J Am Acad Dermatol · 2023-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial. PMID 37352880 · Lancet Infect Dis · 2023-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
GOunder/Desmoid Tumor Research Foundation DEsmoid Symptom/Impact Scale (GODDESS©): psychometric properties and clinically meaningful thresholds as assessed in the Phase 3 DeFi randomized controlled clinical trial. PMID 37347393 · Qual Life Res · 2023-Oct The study is a Phase III randomized trial with a drug intervention in oncology, but it does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). It is a psychometric/quality-of-life analysis of a patient-reported outcome tool.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. PMID 37319109 · J Eur Acad Dermatol Venereol · 2023-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. PMID 37302406 · Lancet Infect Dis · 2023-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2). PMID 37285925 · Ophthalmology · 2023-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study. PMID 37262309 · J Eur Acad Dermatol Venereol · 2023-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial. PMID 36648627 · Infection · 2023-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline Characteristics. PMID 35292925 · Child Psychiatry Hum Dev · 2023-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The effects of abaloparatide on hip geometry and biomechanical properties in Japanese osteoporotic patients assessed using DXA-based hip structural analysis: results of the Japanese phase 3 ACTIVE-J trial. PMID 38030806 · Arch Osteoporos · 2023-Nov-30 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial. PMID 37466374 · Clin Infect Dis · 2023-Nov-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Quality assurance in a phase III, multicenter, randomized trial of POstmastectomy radioThErapy in Node posiTive breast cancer with or without Internal mAmmary nodaL irradiation (POTENTIAL): a planning benchmark case. PMID 38031125 · Radiat Oncol · 2023-Nov-29 This is a planning benchmark case report for a phase III randomized trial evaluating radiotherapy (internal mammary nodal irradiation) in breast cancer. It reports on radiation plan quality and protocol compliance, not on a time-to-event efficacy endpoint like OS or PFS. While it is from a randomized, phase III oncology trial, it lacks a drug-containing intervention and a primary time-to-event efficacy endpoint, making it ineligible.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Effectiveness of low-intensity atorvastatin 5 mg and ezetimibe 10 mg combination therapy compared with moderate-intensity atorvastatin 10 mg monotherapy: A randomized, double-blinded, multi-center, phase III study. PMID 38013289 · Medicine (Baltimore) · 2023-Nov-24 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The effects of safinamide according to gender in Chinese parkinsonian patients. PMID 37996493 · Sci Rep · 2023-Nov-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials. PMID 37990162 · BMC Cancer · 2023-Nov-21 The study is a randomized Phase III trial in oncology with drug intervention, but the primary endpoint is peripheral blood stem cell mobilization and collection, not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). It is a secondary analysis of a secondary endpoint, not the primary efficacy report of the trial.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH. PMID 37406251 · J Clin Endocrinol Metab · 2023-Nov-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Detailed statistical analysis plan for a secondary Bayesian analysis of the SafeBoosC-III trial: a multinational, randomised clinical trial assessing treatment guided by cerebral oximetry monitoring versus usual care in extremely preterm infants. PMID 37974280 · Trials · 2023-Nov-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease. PMID 37966285 · N Engl J Med · 2023-Nov-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis. PMID 36789577 · Gut Liver · 2023-Nov-15 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
[Effect of recombinant human thrombin for hemostasis in liver resection: a randomized controlled phase Ⅲ clinical trial]. PMID 37963740 · Zhonghua Yi Xue Za Zhi · 2023-Nov-14 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. PMID 37858323 · Lancet · 2023-Nov-11 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial. PMID 37335963 · Clin Infect Dis · 2023-Nov-11 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial. PMID 37945292 · BMJ Open · 2023-Nov-09 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial. PMID 37246913 · Sleep · 2023-Nov-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial. PMID 37786396 · JAMA · 2023-Nov-07 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme. PMID 37700689 · J Antimicrob Chemother · 2023-Nov-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial. PMID 37863084 · Lancet · 2023-Nov-04 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial. PMID 37778358 · Lancet · 2023-Nov-04 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Reduced Use of Antibiotics and Nasal Decongestants During Treatment with a Mouthwash Containing Delmopinol. PMID 37916545 · Oral Health Prev Dent · 2023-Nov-02 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in Germany. PMID 37827966 · Vaccine · 2023-Nov-02 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -